Study Flags Potential Benefit of Targeted Medication Reviews

The Part D Enhanced Medication Therapy Management Model launched in 2017 with the intention of incentivizing prescription drug plans (PDPs) to investigate new strategies to optimize medication therapy management (MTM) programs and ultimately reduce Medicare costs. This five-year program, launched across five different Part D regions, is about to come to an end, raising questions such as: What are some of the lessons learned? How could expanding the scope of traditional MTM programs improve outcomes?

Health care solutions company Tabula Rasa HealthCare partnered with Blue Cross and Blue Shield Northern Plains Alliance, a model participant, to improve its MTM program. Now, the company has published a series of papers in the American Journal of Managed Care (AJMC) demonstrating how identifying at-risk patients and optimizing medication regimens at the pharmacist level can impact health care costs and outcomes for Medicare beneficiaries.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

pills
September 22

Report Shows Limited Access to Opioid Use Disorder Treatments for Medicare Beneficiaries

READ MORE
cms-website
September 22

Drug Price Negotiation Will Require New CMS Regulations, Staffing

READ MORE
fda-sign
September 22

Accelerated Approval Prices Are Unrelated to Clinical Value, Study Says

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today